Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

ntial effect of C1-INH in Refractory Paroxysmal Nocturnal Hemoglobinuria (PNH). ViroPharma plans to continue to conduct both clinical and non-clinical studies to evaluate additional therapeutic uses for its C1 INH product in the future.
  • Maribavir for cytomegalovirus – We are currently enrolling patients into a Phase 2 program to evaluate maribavir for the treatment of CMV infections in transplant recipients.  The program consists of two independent Phase 2 clinical studies that include subjects who have asymptomatic CMV in one trial, and those who have failed therapy with other anti-CMV agents in another trial.  Additional data from these ongoing studies will be provided during today's conference call.
  • VP-20629 for Friedreich's Ataxia (FA) – We expect to initiate a single and repeat dose phase 1 study in patients in 2013.
  • Oral Budesonide for eosinophilic esophagitis (EOE) – We currently have an exclusive option agreement to acquire Meritage Pharma, Incorporated based on predefined terms pending data outcomes from a Phase 2 study and concurrence with the U.S. FDA on an acceptable clinical endpoint for the Phase 3 program.  The Phase 2 study is currently enrolling with data expected in 2014.
  • 2013 Guidance ViroPharma is providing guidance for the year 2013 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

    For the year 2013, ViroPharma is providing the following update: 

  • Worldwide net product sales are expected to be $440 to $465 million;  
  • Net North American Cinryze sales are expected to be $390 to $400 million; and
  • Research and development (R&D) and selling, general
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/18/2014)... -- According to the new research ... Wastewater Treatment and Industrial Wastewater Treatment), By Type ... Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends & ... for membrane bioreactor systems is projected to reach ... of 15.28% between 2014 and 2019. ...
    (Date:8/18/2014)... Fla. , Aug. 18, 2014 ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... has filed a Registration Statement on Form 10 ... "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
    (Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
    (Date:8/16/2014)... the Walmart Foundation to build a robotic small motors ... costs of goods, allowing those goods to be produced ... , The Walmart U.S. Manufacturing Innovation Grant was part ... seven research and development institutions at the 2014 U.S. ... between Walmart, the U.S. Conference of Mayors and the ...
    Breaking Biology Technology:Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
    ... Today GenVec, Inc. (NASDAQ: GNVC ) announced financial ... 2011.  For the year ended December 31, 2011, the Company ... share, compared with a net loss of $12.3 million, or ... GenVec ended the year with $26.4 million in cash, cash ...
    ... doubt that the United States will be the No. ... by the year 2020, according to a new national ... deep concerns among Americans about the country,s ability to ... before the next decade. "A lackluster investment in ...
    ... for someone outside of a specialist field to identify ... data can be bewildering. New research, published in BioMed ... , describes a method of social network analysis, similar ... scientific literature and news articles to identify opinion leaders ...
    Cached Biology Technology:GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 6More than half of Americans doubt US global leadership in 2020 2Social networking shortcut to finding medical experts 2
    (Date:8/19/2014)... 2014A new ovoid structure discovered in the Nakhla Martian ... variety of minerals, and shows evidence of undergoing a ... the permafrost and mixing of surface and subsurface fluids. ... analytical studies to determine the origin of this new ... ovoid formed, point to the most likely conclusion, and ...
    (Date:8/19/2014)... in French . ... RISKS of physical activity in children,Today the Canadian Society ... of childhood physical activity and published their position and ... Metabolism ( APNM ). This position stand ... of risk of physical activity for children and suggests ...
    (Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
    Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3Sequencing at sea 2Sequencing at sea 3
    ... latch onto blood platelets rapidly create healthy clots and ... hour after injury, new research shows. "We knew ... now we know the bleeding is stopped in time ... professor of biomedical engineering at Case Western Reserve University ...
    ... polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice ... prevent or arrest osteoporosis than currently available treatments. ... to show that an injection of a polyclonal antipeptide ... and building bone, say researchers at the Mount Sinai ...
    ... supports the possibility that daily vitamin D supplementation can reduce ... that will appear in the journal Pediatrics and ... that vitamin D supplementation decreased the risk of respiratory infections ... at the start of the study. "Our randomized ...
    Cached Biology News:Nanoparticles added to platelets double internal injury survival rate 2Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis 2Vitamin D supplementation can decrease risk of respiratory infections in children 2Vitamin D supplementation can decrease risk of respiratory infections in children 3
    ... Bruker Daltonics and Bruker BioSpins ... for metabolism studies, and analysis of ... ESI-TOF system, an optional Avance NMR ... acquisition, evaluation and statistical analysis for ...
    ... Tracker w/ OutputCumulates a score of movement counts, ... that it.can track up to 6 subjects at ... be triggered. Can outpt a sync pulse ... Can use animal location and timing information ...
    ... fermentation systems for cultivation of microorganisms and ... of bio-pharmaceutical products maximum performance and economy ... and cell fermentation 10 L 1,500 ... ,*Fully automated control system ,*High-quality ...
    tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
    Biology Products: